Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CCAAT/Enhancer-Binding Protein Delta (C/EBPδ): A Previously Unrecognized Tumor Suppressor that Limits the Oncogenic Potential of Pancreatic Ductal Adenocarcinoma Cells.
Hartl L, Duitman J, Aberson HL, Chen K, Dijk F, Roelofs JJTH, Dings MPG, Hooijer GKJ, Hernanda PY, Pan Q, Busch OR, Besselink MGH, Boerman T, Peppelenbosch MP, Bijlsma MF, Spek CA. Hartl L, et al. Among authors: hooijer gkj. Cancers (Basel). 2020 Sep 7;12(9):2546. doi: 10.3390/cancers12092546. Cancers (Basel). 2020. PMID: 32906832 Free PMC article.
Author Correction: Genomic footprints of activated telomere maintenance mechanisms in cancer.
Sieverling L, Hong C, Koser SD, Ginsbach P, Kleinheinz K, Hutter B, Braun DM, Cortés-Ciriano I, Xi R, Kabbe R, Park PJ, Eils R, Schlesner M; PCAWG-Structural Variation Working Group; Brors B, Rippe K, Jones DTW, Feuerbach L; PCAWG Consortium. Sieverling L, et al. Nat Commun. 2022 Dec 8;13(1):7574. doi: 10.1038/s41467-022-32328-7. Nat Commun. 2022. PMID: 36481818 Free PMC article. No abstract available.
Author Correction: The evolutionary history of 2,658 cancers.
Gerstung M, Jolly C, Leshchiner I, Dentro SC, Gonzalez S, Rosebrock D, Mitchell TJ, Rubanova Y, Anur P, Yu K, Tarabichi M, Deshwar A, Wintersinger J, Kleinheinz K, Vázquez-García I, Haase K, Jerman L, Sengupta S, Macintyre G, Malikic S, Donmez N, Livitz DG, Cmero M, Demeulemeester J, Schumacher S, Fan Y, Yao X, Lee J, Schlesner M, Boutros PC, Bowtell DD, Zhu H, Getz G, Imielinski M, Beroukhim R, Sahinalp SC, Ji Y, Peifer M, Markowetz F, Mustonen V, Yuan K, Wang W, Morris QD; PCAWG Evolution & Heterogeneity Working Group; Spellman PT, Wedge DC, Van Loo P; PCAWG Consortium. Gerstung M, et al. Nature. 2023 Feb;614(7948):E42. doi: 10.1038/s41586-022-05601-4. Nature. 2023. PMID: 36697833 Free PMC article. No abstract available.
The repertoire of mutational signatures in human cancer.
Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, Boot A, Covington KR, Gordenin DA, Bergstrom EN, Islam SMA, Lopez-Bigas N, Klimczak LJ, McPherson JR, Morganella S, Sabarinathan R, Wheeler DA, Mustonen V; PCAWG Mutational Signatures Working Group; Getz G, Rozen SG, Stratton MR; PCAWG Consortium. Alexandrov LB, et al. Nature. 2020 Feb;578(7793):94-101. doi: 10.1038/s41586-020-1943-3. Epub 2020 Feb 5. Nature. 2020. PMID: 32025018 Free PMC article.
The dynamics of HER2 status in esophageal adenocarcinoma.
Creemers A, Ebbing EA, Hooijer GKJ, Stap L, Jibodh-Mulder RA, Gisbertz SS, van Berge Henegouwen MI, van Montfoort ML, Hulshof MCCM, Krishnadath KK, van Oijen MGH, Bijlsma MF, Meijer SL, van Laarhoven HWM. Creemers A, et al. Among authors: hooijer gkj. Oncotarget. 2018 Jun 1;9(42):26787-26799. doi: 10.18632/oncotarget.25507. eCollection 2018 Jun 1. Oncotarget. 2018. PMID: 29928485 Free PMC article.
Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma.
Ebbing EA, van der Zalm AP, Steins A, Creemers A, Hermsen S, Rentenaar R, Klein M, Waasdorp C, Hooijer GKJ, Meijer SL, Krishnadath KK, Punt CJA, van Berge Henegouwen MI, Gisbertz SS, van Delden OM, Hulshof MCCM, Medema JP, van Laarhoven HWM, Bijlsma MF. Ebbing EA, et al. Among authors: hooijer gkj. Proc Natl Acad Sci U S A. 2019 Feb 5;116(6):2237-2242. doi: 10.1073/pnas.1820459116. Epub 2019 Jan 22. Proc Natl Acad Sci U S A. 2019. PMID: 30670657 Free PMC article.
Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study).
Schokker S, van der Woude SO, van Kleef JJ, van Zoen DJ, van Oijen MGH, Mearadji B, Beenen LFM, Stroes CI, Waasdorp C, Jibodh RA, Creemers A, Meijer SL, Hooijer GKJ, Punt CJA, Bijlsma MF, van Laarhoven HWM. Schokker S, et al. Among authors: hooijer gkj. Cancers (Basel). 2019 Jun 14;11(6):827. doi: 10.3390/cancers11060827. Cancers (Basel). 2019. PMID: 31207904 Free PMC article.
50 results